Lineage Cell Therapeutics (LCTX) Revenue (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Revenue of $1.7 million for Q1 2026, up 14.85% year-over-year from $1.5 million in Q1 2025, and down 73.9% quarter-over-quarter from $6.6 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Revenue (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Revenue rose 14.85% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $14.8 million (up 54.64% YoY), while the FY2025 annual figure was $14.6 million, up 53.24% from the prior year.
- Revenue for Q1 2026 stood at $1.7 million, down from $6.6 million in the prior quarter.
- The five-year high for Revenue was $6.6 million in Q4 2025, with the low at $1.2 million in Q3 2023.
- The 5-year median for Revenue is $2.8 million (2025), against an average of $2.9 million.
- Peak annual rise in Revenue reached 1239.39% in 2022, while the deepest fall reached 96.17% in 2022.
- Lineage Cell Therapeutics' Revenue stood at $1.9 million in 2022, then increased by 9.03% to $2.1 million in 2023, then surged by 37.36% to $2.9 million in 2024, then soared by 130.4% to $6.6 million in 2025, then slumped by 73.9% to $1.7 million in 2026.
- Business Quant data shows LCTX's Revenue at $1.7 million in Q1 2026, $6.6 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 6.61 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 2.39 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 4.55 Mn |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Sep 30, 2021 | 2.27 Mn |